ISDA: 5L30

Deposition Date 2016-08-02

Release Date 2016-09-28

Last Version Date 2024-10-30

Entry Detail

PDB ID:

5L30

Keywords:

Hydrolase/Hydrolase Inhibitor

Title:

Factor VIIa in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Cricetinae

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.73 Å

R-Value Free:

0.19

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor VII (Heavy Chain)
Gene (Uniprot):F7
Chain IDs:A (auth: H)
Chain Length:254
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF14670 EC:3.4.21.21

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor VII (Light Chain)
Gene (Uniprot):F7
Chain IDs:B (auth: L)
Chain Length:58
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P08709 Pfam ID:PF00089, PF14670 EC:3.4.21.21

Ligand Molecules

70A

GOL

SO4

Primary Citation

Synthesis and P1' SAR exploration of potent macrocyclic tissue factor-factor VIIa inhibitors.

Ladziata, V.U, Glunz, P.W, Zou, Y, Zhang, X, Jiang, W, Jacutin-Porte, S, Cheney, D.L, Wei, A, Luettgen, J.M, Harper, T.M, Wong, P.C, Seiffert, D, Wexler, R.R, Priestley, E.S.Show

Bioorg.Med.Chem.Lett. 26 5051 5057 (2016)

PMID: 27612545 DOI: 10.1016/j.bmcl.2016.08.088

Abstact

Selective tissue factor-factor VIIa complex (TF-FVIIa) inhibitors are viewed as promising compounds for treating thrombotic disease. In this contribution, we describe multifaceted exploratory SAR studies of S1'-binding moieties within a macrocyclic chemotype aimed at replacing cyclopropyl sulfone P1' group. Over the course of the optimization efforts, the 1-(1H-tetrazol-5-yl)cyclopropane P1' substituent emerged as an improved alternative, offering increased metabolic stability and lower clearance, while maintaining excellent potency and selectivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form